Literature DB >> 8922394

Distinct regions control transcriptional activation of the alpha1(VI) collagen promoter in different tissues of transgenic mice.

P Braghetta1, C Fabbro, S Piccolo, D Marvulli, P Bonaldo, D Volpin, G M Bressan.   

Abstract

To identify regions involved in tissue specific regulation of transcription of the alpha1(VI) collagen chain, transgenic mice were generated carrying various portions of the gene's 5'-flanking sequence fused to the E. coli beta-galactosidase gene. Analysis of the transgene expression pattern by X-gal staining of embryos revealed that: (a) The proximal 0.6 kb of promoter sequence activated transcription in mesenchymal cells at sites of insertion of superficial muscular aponeurosis into the skin; tendons were also faintly positive. (b) The region between -4.0 and -5.4 kb from the transcription start site was required for activation of the transgene in nerves. It also drove expression in joints, in intervertebral disks, and in subepidermal and vibrissae mesenchyme. (c) The fragment comprised within -6.2 and -7.5 kb was necessary for high level transcription in skeletal muscle and meninges. Positive cells in muscle were mostly mononuclear and probably included connective tissue elements, although staining of myoblasts was not ruled out. This fragment also activated expression in joints, in intervertebral disks, and in subepidermal and vibrissae mesenchyme. (d) beta-Galactosidase staining in vibrissae induced by the sequences -4.0 to -5.4 and -6.2 to -7.5 was not coincident: with the latter sequence labeled nuclei were found mainly in the ventral and posterior quadrant, and, histologically, in the outer layers of mesenchyme surrounding and between the follicles, whereas with the former the remaining quadrants were positive and expressing cells were mostly in the inner layers of the dermal sheath. (e) Other tissues, notably lung, adrenal gland, digestive tract, which produce high amounts of collagen type VI, did not stain for beta-galactosidase. (f) Central nervous system and retina, in which the endogenous gene is inactive, expressed the lacZ transgene in most lines. The data suggest that transcription of alpha1(VI) in different tissues is regulated by distinct sequence elements in a modular arrangement, a mechanism which confers high flexibility in the temporal and spatial pattern of expression during development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922394      PMCID: PMC2133380          DOI: 10.1083/jcb.135.4.1163

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  30 in total

1.  Expression of neurofilament proteins in granule cells of the cerebellum.

Authors:  M Vitadello; S Denis-Donini
Journal:  Brain Res       Date:  1990-02-12       Impact factor: 3.252

2.  The superficial musculo-aponeurotic system (SMAS) in the parotid and cheek area.

Authors:  V Mitz; M Peyronie
Journal:  Plast Reconstr Surg       Date:  1976-07       Impact factor: 4.730

3.  Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues.

Authors:  P Bonaldo; V Russo; F Bucciotti; R Doliana; A Colombatti
Journal:  Biochemistry       Date:  1990-02-06       Impact factor: 3.162

4.  Identification of a phenotype-specific enhancer in the first intron of the rat collagen II gene.

Authors:  W Horton; T Miyashita; K Kohno; J R Hassell; Y Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Tissue-specific expression of the human type II collagen gene in mice.

Authors:  R H Lovell-Badge; A Bygrave; A Bradley; E Robertson; R Tilly; K S Cheah
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Type VI collagen. In situ hybridizations and immunohistochemistry reveal abundant mRNA and protein levels in human neurofibroma, schwannoma and normal peripheral nerve tissues.

Authors:  J Peltonen; S Jaakkola; L L Hsiao; R Timpl; M L Chu; J Uitto
Journal:  Lab Invest       Date:  1990-04       Impact factor: 5.662

7.  Cloning and regulation of a mRNA specifically expressed in the preadipose state.

Authors:  C Dani; A Doglio; E Z Amri; S Bardon; P Fort; B Bertrand; P Grimaldi; G Ailhaud
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

8.  Spatial and temporal changes of type VI collagen expression during mouse development.

Authors:  D Marvulli; D Volpin; G M Bressan
Journal:  Dev Dyn       Date:  1996-08       Impact factor: 3.780

9.  Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells.

Authors:  D Pavlin; A C Lichtler; A Bedalov; B E Kream; J R Harrison; H F Thomas; G A Gronowicz; S H Clark; C O Woody; D W Rowe
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

10.  Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network.

Authors:  D R Keene; E Engvall; R W Glanville
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

View more
  13 in total

Review 1.  The Role of Collagens in Peripheral Nerve Myelination and Function.

Authors:  Peiwen Chen; Matilde Cescon; Paolo Bonaldo
Journal:  Mol Neurobiol       Date:  2014-08-21       Impact factor: 5.590

Review 2.  Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies.

Authors:  Paolo Bernardi; Paolo Bonaldo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

3.  ColVI myopathies: where do we stand, where do we go?

Authors:  Valérie Allamand; Laura Briñas; Pascale Richard; Tanya Stojkovic; Susana Quijano-Roy; Gisèle Bonne
Journal:  Skelet Muscle       Date:  2011-09-23       Impact factor: 4.912

4.  Extensive phenotypic characterization of a new transgenic mouse reveals pleiotropic perturbations in physiology due to mesenchymal hGH minigene expression.

Authors:  Aimilios Kaklamanos; Jan Rozman; Manolis Roulis; Niki Karagianni; Maria Armaka; Moya Wu; Laura Brachthäuser; Julia Calzada-Wack; Marion Horsch; Johannes Beckers; Birgit Rathkolb; Thure Adler; Frauke Neff; Eckhard Wolf; Valerie Gailus-Durner; Helmut Fuchs; Martin Hrabe de Angelis; George Kollias
Journal:  Sci Rep       Date:  2017-05-25       Impact factor: 4.379

5.  Muscle Weakness and Fibrosis Due to Cell Autonomous and Non-cell Autonomous Events in Collagen VI Deficient Congenital Muscular Dystrophy.

Authors:  Satoru Noguchi; Megumu Ogawa; May Christine Malicdan; Ikuya Nonaka; Ichizo Nishino
Journal:  EBioMedicine       Date:  2016-12-23       Impact factor: 8.143

6.  Comparison between Collagen and Lidocaine Intramuscular Injections in Terms of Their Efficiency in Decreasing Myofascial Pain within Masseter Muscles: A Randomized, Single-Blind Controlled Trial.

Authors:  Aleksandra Nitecka-Buchta; Karolina Walczynska-Dragon; Jolanta Batko-Kapustecka; Mieszko Wieckiewicz
Journal:  Pain Res Manag       Date:  2018-06-03       Impact factor: 3.037

7.  Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.

Authors:  Maria Armaka; Maria Apostolaki; Peggy Jacques; Dimitris L Kontoyiannis; Dirk Elewaut; George Kollias
Journal:  J Exp Med       Date:  2008-02-04       Impact factor: 14.307

8.  Different cis-regulatory DNA elements mediate developmental stage- and tissue-specific expression of the human COL2A1 gene in transgenic mice.

Authors:  K K Leung; L J Ng; K K Ho; P P Tam; K S Cheah
Journal:  J Cell Biol       Date:  1998-06-15       Impact factor: 10.539

Review 9.  How to build an inducible cartilage-specific transgenic mouse.

Authors:  Esmeralda N Blaney Davidson; Fons A J van de Loo; Wim B van den Berg; Peter M van der Kraan
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

10.  Lack of collagen VI promotes neurodegeneration by impairing autophagy and inducing apoptosis during aging.

Authors:  Matilde Cescon; Peiwen Chen; Silvia Castagnaro; Ilaria Gregorio; Paolo Bonaldo
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.